Antitumor effect of recombinant mouse interleukin-33 in mice

JIANG Liya; LUO Ping; DENG Shaorong; YE Hao; YU Yan; HAN Wei

doi:10.11665/j.issn.1000-5048.20200510

Journal of China Pharmaceutical University > 2020 > 51(5): 584-590. > DOI: 10.11665/j.issn.1000-5048.20200510

JIANG Liya, LUO Ping, DENG Shaorong, YE Hao, YU Yan, HAN Wei. Antitumor effect of recombinant mouse interleukin-33 in mice[J]. Journal of China Pharmaceutical University, 2020, 51(5): 584-590. DOI: 10.11665/j.issn.1000-5048.20200510

Citation:

PDF (635 KB)

Antitumor effect of recombinant mouse interleukin-33 in mice

Funds: This study was supported by the National Natural Science Foundation of China (No.81673446/H3105)

More Information

Received Date: November 17, 2019
Revised Date: September 21, 2020

Graphical Abstract

Abstract

Abstract

To explore the effect of IL-33 on various tumor types,exogenous injection of recombinant mouse IL-33 protein (mIL-33) was used to study the efficacy of different subcutaneous tumor-bearing mouse models. In this study,mIL-33 has been found to significantly inhibit the growth of liver,lung,gastric,prostate,and colon cancers. However,the inhibition of tumor growth by mIL-33 was not completely consistent in different types of tumor. A lower dose of mIL-33 (10 μg/kg) significantly inhibited tumor growth in subcutaneous tumor-bearing mice of liver,lung,and gastric cancers,while a higher dose of mIL-33 (90 μg/kg) was required to exert the corresponding antitumor effect in subcutaneous tumor-bearing mouse models with prostate and colon cancers. In addition,the growth inhibitory effect of mIL-33 on subcutaneous tumors of colon cancer was also correlated with the duration of administration and the stage of tumor progression. The results of this study indicate that mIL-33 significantly inhibits the growth of a variety of tumors,suggesting that IL-33 might be an effective target for tumor treatment.
- mIL-33,
- antitumor,
- liver cancer,
- lung cancer,
- prostate cancer,
- colon cancer

FullText(HTML)

References (23)

References

[1]	. Immunol Rev，2018，281（1）：154?168.
[2]	de la Fuente M，MacDonald TT，Hermoso MA. The IL-33/ST2 axis：role in health and disease［J］. Cytokine Growth Factor Rev，2015，26（6）：615?623.
[3]	Yang Y，Wang JB，Li YM，et al. Role of IL-33 expression in oncogenesis and development of human hepatocellular carcinoma［J］. Oncol Lett，2016，12（1）：429?436.
[4]	Zhang P，Liu XK，Chu Z，et al. Detection of interleukin-33 in serum and carcinoma tissue from patients with hepatocellular carcinoma and its clinical implications［J］. J Int Med Res，2012，40（5）：1654?1661.
[5]	Jin ZQ，Lei L，Lin DD，et al. IL-33 released in the liver inhibits tumor growth via promotion of CD4⁺ and CD8⁺ T cell responses in hepatocellular carcinoma［J］. J Immunol，2018，201（12）：3770?3779.
[6]	Deng X，Xiong YQ，Ma B，et al. Expression of interleukin-33 in non-small cell lung cancer patients and its clinical significance［J］. Chin J Exp Surg（中华实验外科杂志），2016，33（4）：1122?1125.
[7]	Gao K，Li XY，Zhang L，et al. Transgenic expression of IL-33 activates CD8⁺ T cells and NK cells and inhibits tumor growth and metastasis in mice［J］. Cancer Lett，2013，335（2）：463?471.
[8]	Deng KY，Wang H，Shan T，et al. Tristetraprolin inhibits gastric cancer progression through suppression of IL-33［J］. Sci Rep，2016，6：24505.
[9]	Eissmann MF，Dijkstra C，Jarnicki A，et al. IL-33-mediated mast cell activation promotes gastric cancer through macrophage mobilization［J］. Nat Commun，2019，10（1）：2735.
[10]	Saranchova I，Han J，Huang H，et al. Discovery of a metastatic immune escape mechanism initiated by the loss of expression of the tumour biomarker interleukin-33［J］. Sci Rep，2016，6：30555.
[11]	Zhou YX，Ji Y，Wang HG，et al. IL-33 promotes the development of colorectal cancer through inducing tumor-infiltrating ST2L⁺ regulatory T cells in mice［J］. Technol Cancer Res Treat，2018，17：1533033818780091.
[12]	Zhang Y，Davis C，Shah S，et al. IL-33 promotes growth and liver metastasis of colorectal cancer in mice by remodeling the tumor microenvironment and inducing angiogenesis［J］. Mol Carcinog，2017，56（1）：272?287.
[13]	Xia YL，Ohno T，Nishii N，et al. Endogenous IL-33 exerts CD8⁺ T cell antitumor responses overcoming pro-tumor effects by regulatory T cells in a colon carcinoma model［J］. Biochem Biophys Res Commun，2019，518（2）：331?336.
[14]	O''''Donnell C，Mahmoud A，Keane J，et al. An antitumorigenic role for the IL-33 receptor，ST2L，in colon cancer［J］. Br J Cancer，2016，114（1）：37?43.
[15]	Eissmann MF，Dijkstra C，Wouters MA，et al. Interleukin 33 signaling restrains sporadic colon cancer in an interferon-γ-dependent manner［J］. Cancer Immunol Res，2018，6（4）：409?421.
[16]	Luo P，Deng SR，Ye H，et al. The IL-33/ST2 pathway suppresses murine colon cancer growth and metastasis by upregulating CD40 L signaling［J］. Biomed Pharmacother，2020，127：110232.
[17]	Gao Q，Han Y，Xu W，et al. Combination of a single-chain variable fragment JZC00 with 2-deoxyglucose inhibited tumor growth in murine models［J］. J China Pharm Univ（中国药科大学学报），2020，51（2）：206?212.
[18]	Deng SR，Deng Q，Zhang YJ，et al. Non-platelet-derived CXCL4 differentially regulates cytotoxic and regulatory T cells through CXCR3 to suppress the immune response to colon cancer［J］. Cancer Lett，2019，443：1?12.
[19]	Wang KL，Shan S，Yang ZJ，et al. IL-33 blockade suppresses tumor growth of human lung cancer through direct and indirect pathways in a preclinical model［J］. Oncotarget，2017，8（40）：68571?68582.
[20]	Wang CH，Chen ZS，Bu XM，et al. IL-33 signaling fuels outgrowth and metastasis of human lung cancer［J］. Biochem Biophys Res Commun，2016，479（3）：461?468.
[21]	He ZX，Chen LL，Souto FO，et al. Epithelial-derived IL-33 promotes intestinal tumorigenesis in Apc ^Min/+ mice［J］. Sci Rep，2017，7（1）：5520.
[22]	Lu BF，Yang M，Wang QQ. Interleukin-33 in tumorigenesis，tumor immune evasion，and cancer immunotherapy［J］. J Mol Med，2016，94（5）：535?543.
[23]	Fournié JJ，Poupot M. The pro-tumorigenic IL-33 involved in antitumor immunity：a Yin and Yang cytokine［J］. Front Immunol，2018，9：2506.

[1]	ZHANG Ying, WANG Di, ZHANG Pei, ZHANG Zunjian, XU Fengguo. Metabolomic study on the effects of insulin and oleic acid on the development of colon cancer xenografts[J]. Journal of China Pharmaceutical University, 2021, 52(3): 339-345. DOI: 10.11665/j.issn.1000-5048.20210311
[2]	CHEN Xian, GUO Wenjing, YANG Liliang, ZHOU Yuxin, GUO Qinglong. Research progress on the role of heat shock protein 27 in prostate cancer[J]. Journal of China Pharmaceutical University, 2020, 51(6): 731-738. DOI: 10.11665/j.issn.1000-5048.20200613
[3]	CHANG Hui, ZHANG Yameng, DING Xuansheng. Research progress on lipid metabolism in non-small cell lung cancer[J]. Journal of China Pharmaceutical University, 2020, 51(1): 107-113. DOI: 10.11665/j.issn.1000-5048.20200116
[4]	CHEN Jiajia, BEI Yuncheng, ZHANG Dongmei, SHEN Pingping. Combination of artemether with etoposide inhibits cell proliferation and invasion in small cell lung cancer cell line H446[J]. Journal of China Pharmaceutical University, 2017, 48(2): 201-207. DOI: 10.11665/j.issn.1000-5048.20170211
[5]	YANG Peishu, HAO Wenli. Inhibitory effect and its mechanism of 7-O-succinyl macrolactin A against cell proliferation, invasion and migration in human lung cancer H460 cells[J]. Journal of China Pharmaceutical University, 2017, 48(1): 82-88. DOI: 10.11665/j.issn.1000-5048.20170113
[6]	SUN Zhuolin, LIU Jingwei, KUANG Changchun. Inhibitions and mechanisms of amygdalin in non-small cell lung cancer NCI-H1299 cell line invasion in vitro[J]. Journal of China Pharmaceutical University, 2016, 47(4): 479-482. DOI: 10.11665/j.issn.1000-5048.20160415
[7]	CAO Rongyue, CHANG Na, LI Manman, WANG Yunkang, WU Di, SHI Baoying, YUAN Yuting, LONG Jun. Preparation of mGM-CSF/βhCG fusion protein and the effect of its sensitized DC vaccine on RM-1 prostate tumor in mice[J]. Journal of China Pharmaceutical University, 2015, 46(1): 111-116. DOI: 10.11665/j.issn.1000-5048.20150117
[8]	ZHAO Leilei, ZHANG Yuan, ZHOU Jinpei, ZHANG Huibin. Advances in research on drugs targeting non-small cell lung cancer[J]. Journal of China Pharmaceutical University, 2014, 45(2): 136-144. DOI: 10.11665/j.issn.1000-5048.20140202
[9]	HU Shan, DENG Yongchuan. Mechanism of isorhamnetin on breast cancer cells[J]. Journal of China Pharmaceutical University, 2013, 44(6): 563-567. DOI: 10.11665/j.issn.1000-5048.20130615

Cited By

Cited by

Periodical cited type(1)

徐俪菲，王宇. 荷瘤小鼠血清中细胞因子表达谱分析. 锦州医科大学学报. 2021(06): 1-6 .

Other cited types(0)

Get Citation

PDF

XML

Article views (139) PDF downloads (528) Cited by(1)

Turn off MathJax

Article Contents

Abstract

References

Antitumor effect of recombinant mouse interleukin-33 in mice

Abstract

References

Related Articles

Cited by

Periodical cited type(1)

Other cited types(0)

Catalog

Antitumor effect of recombinant mouse interleukin-33 in mice

Abstract

References

Related Articles

Cited by

Periodical cited type(1)

Other cited types(0)

Catalog

Export File

Citation

Format

Content